Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLVQKF)

Drug Name

MRX-6 Drug Info

Synonyms

CXCL10 gene inhibitor/phospholipase A2/ MIP 1 ligand inhibitor (contact dermatitis), Morria Biopharmaceuticals; IL 1 beta/IL-6/PGE 2 modulator (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Monocyte chemotactic protein 1/GM-CSF/TNF alpha ligand inhibitor (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Non-steroidal multifunctional anti-inflammatory drug (MFAID) (topical formulation, contact dermatitis), Morria

Indication

Disease Entry	ICD 11	Status	REF
Contact dermatitis	EK0Z	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMLVQKF

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Phospholipase A2 (PLA2G1B)	DTT	PLA2G1B	5.385	3.733	4.178	5.278

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Contact dermatitis

ICD Disease Classification

EK0Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Phospholipase A2 (PLA2G1B)	DTT	PLA2G1B	2.65E-01	-0.08	-0.21

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT02031445) Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%. U.S. National Institutes of Health.
2	A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.